Cash, Cash Equivalents, and Marketable Securities
Moderna Cash, Cash Equivalents, and Marketable Securities increased by 175.0% to $11.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 15.4%, from $13.00M to $11.00M. Over 4 years (FY 2021 to FY 2025), Cash, Cash Equivalents, and Marketable Securities shows a downward trend with a -47.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher levels provide a larger buffer for operational needs and strategic opportunities, while lower levels may indicate tight liquidity or aggressive capital deployment.
Detailed definition
This is the aggregate of all highly liquid assets, including cash, bank deposits, and short-term marketable securities t...
Peer comparison
A fundamental liquidity metric used by all public companies to assess financial health.
cash_equivalents_marketable_securities_totalHistorical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.00M | $271.00M | $378.00M | $549.00M | $464.00M | $348.00M | $335.00M | $268.00M | $151.00M | $125.00M | $94.00M | $34.00M | $28.00M | $13.00M | $9.00M | $5.00M | $4.00M | $11.00M |
| QoQ Change | — | +421.2% | +39.5% | +45.2% | -15.5% | -25.0% | -3.7% | -20.0% | -43.7% | -17.2% | -24.8% | -63.8% | -17.6% | -53.6% | -30.8% | -44.4% | -20.0% | +175.0% |
| YoY Change | — | — | — | — | +792.3% | +28.4% | -11.4% | -51.2% | -67.5% | -64.1% | -71.9% | -87.3% | -81.5% | -89.6% | -90.4% | -85.3% | -85.7% | -15.4% |
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Moderna's cash, cash equivalents, and marketable securities?
- Moderna (MRNA) reported cash, cash equivalents, and marketable securities of $11.00M in Q1 2026.
- How has Moderna's cash, cash equivalents, and marketable securities changed year-over-year?
- Moderna's cash, cash equivalents, and marketable securities decreased by 15.4% year-over-year, from $13.00M to $11.00M.
- What is the long-term trend for Moderna's cash, cash equivalents, and marketable securities?
- Over 4 years (2021 to 2025), Moderna's cash, cash equivalents, and marketable securities has grown at a -47.3% compound annual growth rate (CAGR), from $52.00M to $4.00M.
- What does cash, cash equivalents, and marketable securities mean?
- The total amount of cash and easily sellable investments the company holds.